Souhaitez-vous accéder aux communiqués récents ?
Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord.
-
Financing led by Soleus Capital with participation from Vestal Point Capital, Squadron Capital Management and additional new and existing investors DOYLESTOWN, Pa., March 30, 2026 (GLOBE NEWSWIRE)...
-
BOSTON, March 30, 2026 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage biotechnology company transforming the treatment of autoimmune diseases, today announced the dosing of the first...
-
-- Studies highlight reduced total cost of care and select healthcare resource utilization outcomes in total knee arthroplasty (TKA) and spinal fusion -- BRISBANE, Calif., March 30, 2026 (GLOBE...
-
Tevas Biosimilar PONLIMSI™ ist nun von der FDA für alle Indikationen des Referenzprodukts Prolia® (Denosumab) zur Behandlung verschiedener schwerer Knochenerkrankungen zugelassen.Tevas vorgeschlagener...
-
Le médicament biosimilaire de Teva, PONLIMSI™, est désormais approuvé par la FDA pour toutes les indications du produit de référence, Prolia® (dénosumab), dans le cadre du traitement de diverses...
-
Teva’s biosimilar, PONLIMSI™, is now FDA-approved across all indications of the reference product, Prolia® (denosumab), to treat a variety of debilitating bone conditions.Teva’s proposed biosimilar...
-
- Comprehensive submission includes interim Phase 3 FORTIFY data demonstrating BBP-418’s rapid, consistent treatment effect and favorable safety profile, with statistically significant and clinically...
-
Commercial agreement serves as high-profile third party validation of BullFrog AI’s proprietary capabilities Agreement utilizes BullFrog AI’s end-to-end analytical AI platform to accelerate drug...
-
KING OF PRUSSIA, Pa., March 30, 2026 (GLOBE NEWSWIRE) -- SEED Therapeutics, Inc. (“SEED”), a clinical-stage biotechnology company specializing in molecular glue degraders, today announced that it...
-
Dialogue continues with European Medicines Agency (EMA) to advance the development program of oral blarcamesine in early Alzheimer’s disease Additional data submitted to the U.S. FDA with the...